Tag: neuromyelitis optica spectrum disorder

October 30, 2019 Off

FDA Accepts Genentech’s Biologics License Application for Satralizumab for Neuromyelitis Optica Spectrum Disorder

– Satralizumab represents a potential new approach to treating neuromyelitis optica spectrum disorder (NMOSD), a rare, debilitating disease often misdiagnosed…

March 29, 2017 Off

AstraZeneca’s and MedImmune’s NMOSD drug gets EMA’s orphan designation

By Dino Mustafić

European Medicines Agency (EMA) has granted orphan designation to AstraZeneca’s and MedImmune’s inebilizumab (formerly MEDI-551) for the treatment of neuromyelitis optica spectrum disorder (NMOSD).